Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (478 pages)

ISBN: 1-281-05682-0 , 9786611056827 , 0-08-053775-8

Content: This book offers pertinent basic science information on strategies used for the rational design and discovery of novel anticancer agents, and, in addition, translational studies involving clinical trial design and execution with these novel, mostly cytostatic agents. This book covers basic science strategies that are being used in drug discovery and preclinical evaluation focused on novel molecular targets, as well as clinical trial methodology including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new, relatively non-cytotoxic anticancer agents.

Note: Front Cover; Novel Anticancer Agents: Strategies for Discovery and Clinical Testing; Copyright Page; Contents; Contributors; Preface; Part I: Strategies for Drug Discovery; Chapter 1. A Survey of Novel Molecular Targets for Anticancer Drug Discovery; I. Introduction; II. Overview of Growth Factor Induced Mitogenic Signaling; III. Protein Kinases and Phosphatases; IV. Adapter Proteins; V. GTP-Binding Proteins; VI. Oncogenic Transcription Factors; VII. Apoptosis, Cell Survival, and Life Span Targets; VIII. Angiogenesis and Metastasis Molecular Factors , IX. Protein Degradation and Chaperoning Targets; X. Chromatin Remodeling Factors; XI. Conclusion; References; Chapter 2. Microarrays: Small Spots Produce Major Advances in Pharmacogenomics; I. Introduction to Microarrays; II. Advantages of DNA Microarrays; III. Major DNA Array Formats: Something for Everyone; IV. What is the Best Way to Interface with Microarrays?; V. Microarrays and Pharmacogenomics: Revolutionizing Discovery of New Drugs and Gene Function; VI. What Can Go Wrong in cDNA Microarray Experimentation?; VII. Array-Based Proteomics: How to Investigate Protein Complexity , VIII. Emerging Microarray Technologies for High-Throughput Proteome Investigation: A Technical Overview; IX. Current and Future Applications of Protein Arrays in Drug Discovery; X. How to Deal with all that Data; XI. The Future is Only Going to Get Better; References; Chapter 3. Strategies to Target Chemotherapeutics to Tumors; I. Background and Rationale; II. Antibody-Directed Enzyme Prodrug Technique; III. Passive Tumor Targeting; IV. Targeting by Binding to Tumor Cell Surface Molecules; V. Enzyme-Activated Targeting; VI. Summary and Future Directions; References , Chapter 4. QSAR and Pharmacophore Mapping Strategies in Novel Anticancer Drug Discovery; I. Introduction; II. Pharmacophore Definition; III. Pharmacophore Validation; IV. Conclusions; References; Chapter 5. Applications of Nuclear Magnetic Resonance and Mass Spectrometry to Anticancer Drug Discovery; I. Introduction; II. NMR in Anticancer Drug Discovery; III. Mass Spectrometry in Anticancer Drug Discovery; IV. MS/NMR Screening Assay; V. Conclusions; Acknowledgements; References; Chapter 6. Antisense Strategies for the Development of Novel Cancer Therapeutics; I. Introduction , II. Design and Evaluation of Antisence OligonucleotidesIII. Conclusion; Acknowledgements; References; Chapter 7. Antibodies and Vaccines as Novel Cancer Therapeutics; I. Introduction; II. Anti-Tumor Antibodies; III. Cancer Vaccines; IV. Conclusion; References; Chapter 8. Inhibitors of Apoptosis as Targets for Cancer Therapy; I. The Inhibitors of Apoptosis; II. Concluding Remarks; References; Chapter 9. Preclinical Testing and Validation of Novel Anticancer Agents; I. Introduction; II. Target Validation; III. A Generic Cascade for Anticancer Drug Discovery; IV. High-Throughput Cell-Free Screens for Activity Against the Target , English

Additional Edition: ISBN 0-12-088561-1

Language: English

UID:

Format: 1 online resource (372 p.)

Edition: 1st ed. 2003.

ISBN: 1-280-84257-1 , 9786610842575 , 1-59259-380-1

Series Statement: Methods in Molecular Medicine, 85

Content: With many potential molecular targets of anticancer agents already identified and many more yet to be discovered, the great challenges are now to successfully validate them, to devise relevant assays, and to translate the results into effective medicines for cancer patients. In Novel Anticancer Drug Protocols, expert basic researchers and clinicians from both industry and academia not only survey the whole arena of novel antitumor drug targets, but also present a wide-ranging selection of the key techniques currently being applied throughout anticancer drug discovery and development. Described in step-by-step detail to ensure successful results, these methods are employed in experiments involving such central topics as immunotherapy, angiogenesis, cancer metastasis, the cell cycle, signal transduction inhibitors, apoptosis, antibodies, antisense molecules, microarray gene expression analysis, flow cytometry, and PET imaging for cancer target validation. There are also proven methods for the preclinical identification of drug targets and for target validation during the clinical trials of novel agents. Each method provides background information, easy-to-follow instructions, notes on avoiding pitfalls, and alternative procedures. Eminently practical and user-friendly, Novel Anticancer Drug Protocols offers all researchers involved in cancer drug development a blend of the critical preclinical and clinical assays needed for the target validation and discovery of novel agents today.

Note: Description based upon print version of record. , Overview of Novel Anticancer Drug Targets -- Kinase Inhibitor Discovery Protocols -- Biomarker Assays for Phosphorylated MAP Kinase -- Assays for Cyclin-Dependent Kinase Inhibitors -- Identifying Inhibitors of ATM and ATR Kinase Activities -- Angiogenesis and Metastasis Protocols -- The Rat Aortic Ring Assay for In Vitro Study of Angiogenesis -- Real Time In Vivo Quantitation of Tumor Angiogenesis -- Use of Tumor-Activated Hepatic Stellate Cell as a Target for the Preclinical Testing of Anti-Angiogenic Drugs Against Hepatic Tumor Development -- Cell Motility, Adhesion, Homing, and Migration Assays in the Studies of Tyrosine Kinases -- Inflammatory Response of Tumor-Activated Hepatic Sinusoidal Endothelium as a Target for the Screening of Metastasis Chemopreventive Drugs -- Binding Assay for Selectins -- Determination of Peak Serum Levels and Immune Response to the Humanized Anti-Ganglioside Antibody-Interleukin-2 Immunocytokine -- Immunohistochemical Assays in the Clinical Setting -- Immunohistochemical Determination of EGFR-Tyrosine Kinase Inhibition in Clinical Samples -- Immunohistochemical Assays of Farnesyltransferase Inhibition in Patient Samples -- Protein Chaperoning/Degradation Protocols -- Assays for HSP90 and Inhibitors -- Assays for Proteasome Inhibition -- Protein-Protein and Protein-DNA Interactions -- The Mammalian Two-Hybrid Assay for Detection of Coactivator-Nuclear Receptor Interactions -- Preparation of DNA-Protein Complexes Suitable for Spectroscopic Analysis -- Antisense -- Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression -- Genomics -- Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms -- Gene Expression Microarrays -- Methods for Isolation and Genetic Analysis of Circulating Tumor DNA in Patient Plasma -- Cell Lifespan/Longevity -- The Use of Early Sea Urchin Embryos in Anticancer Drug Testing -- In Vivo Imaging -- PET Screening of Anticancer Drugs -- Miscellaneous Protocols -- Assays for In Vitro and In Vivo Synergy -- Flow Cytometric Methods for Detection and Quantification of Apoptosis -- Assays for Neoplastic Cell Enrichment in Bone Marrow Samples. , English

Additional Edition: ISBN 0-89603-963-3

Language: English

DOI: 10.1385/1592593801

UID:

Format: xv, 437 p.,[20]p. : , ill. (some col.)

Edition: Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.

Language: English

Keywords: Electronic books.

URL: Click to View